BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16884307)

  • 21. Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin.
    Lee YS; Marcu MG; Neckers L
    Chem Biol; 2004 Jul; 11(7):991-8. PubMed ID: 15271357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural studies on the co-chaperone Hop and its complexes with Hsp90.
    Onuoha SC; Coulstock ET; Grossmann JG; Jackson SE
    J Mol Biol; 2008 Jun; 379(4):732-44. PubMed ID: 18485364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
    Kung PP; Huang B; Zhang G; Zhou JZ; Wang J; Digits JA; Skaptason J; Yamazaki S; Neul D; Zientek M; Elleraas J; Mehta P; Yin MJ; Hickey MJ; Gajiwala KS; Rodgers C; Davies JF; Gehring MR
    J Med Chem; 2010 Jan; 53(1):499-503. PubMed ID: 19908836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design.
    Dymock BW; Barril X; Brough PA; Cansfield JE; Massey A; McDonald E; Hubbard RE; Surgenor A; Roughley SD; Webb P; Workman P; Wright L; Drysdale MJ
    J Med Chem; 2005 Jun; 48(13):4212-5. PubMed ID: 15974572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
    Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the chemical diversity of an hsp90 database.
    Audisio D; Messaoudi S; Ijjaali I; Dubus E; Petitet F; Peyrat JF; Brion JD; Alami M
    Eur J Med Chem; 2010 May; 45(5):2000-9. PubMed ID: 20170986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
    J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. hsp90: twist and fold.
    Richter K; Buchner J
    Cell; 2006 Oct; 127(2):251-3. PubMed ID: 17055424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
    Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
    J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor.
    Kim SH; Bajji A; Tangallapally R; Markovitz B; Trovato R; Shenderovich M; Baichwal V; Bartel P; Cimbora D; McKinnon R; Robinson R; Papac D; Wettstein D; Carlson R; Yager KM
    J Med Chem; 2012 Sep; 55(17):7480-501. PubMed ID: 22913511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
    Huth JR; Park C; Petros AM; Kunzer AR; Wendt MD; Wang X; Lynch CL; Mack JC; Swift KM; Judge RA; Chen J; Richardson PL; Jin S; Tahir SK; Matayoshi ED; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Fesik SW; Elmore SW; Hajduk PJ
    Chem Biol Drug Des; 2007 Jul; 70(1):1-12. PubMed ID: 17630989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purine-scaffold Hsp90 inhibitors.
    Chiosis G; Tao H
    IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.
    Brough PA; Barril X; Borgognoni J; Chene P; Davies NG; Davis B; Drysdale MJ; Dymock B; Eccles SA; Garcia-Echeverria C; Fromont C; Hayes A; Hubbard RE; Jordan AM; Jensen MR; Massey A; Merrett A; Padfield A; Parsons R; Radimerski T; Raynaud FI; Robertson A; Roughley SD; Schoepfer J; Simmonite H; Sharp SY; Surgenor A; Valenti M; Walls S; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2009 Aug; 52(15):4794-809. PubMed ID: 19610616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements.
    Shiau AK; Harris SF; Southworth DR; Agard DA
    Cell; 2006 Oct; 127(2):329-40. PubMed ID: 17055434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a novel Hsp90 inhibitor by fragment linking.
    Barker JJ; Barker O; Courtney SM; Gardiner M; Hesterkamp T; Ichihara O; Mather O; Montalbetti CA; Müller A; Varasi M; Whittaker M; Yarnold CJ
    ChemMedChem; 2010 Oct; 5(10):1697-700. PubMed ID: 20665758
    [No Abstract]   [Full Text] [Related]  

  • 38. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
    J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone.
    Kung PP; Sinnema PJ; Richardson P; Hickey MJ; Gajiwala KS; Wang F; Huang B; McClellan G; Wang J; Maegley K; Bergqvist S; Mehta PP; Kania R
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3557-62. PubMed ID: 21612924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.